Sinuvac (SVA) reports swine flu success
Today's Financial News - Posted August 18, 2009
The unexpected absence of the Chinese fencing coach can only be due to one thing: Sinuvac’s (AMEX:SVA) reported a breakthrough with their new anti- H1N1 swine flu vaccine!
by J. Christoph Amberger
Baltimore, MD — TFN: I should’ve seen it coming.
When I asked Bin Lu, my Chinese fencing coach, earlier this summer if he’d be embarking on his annual pilgrimage to China this summer, he seemed dubious.
“Afraid they put me in quarantine,” he said. “Swine flu.”
Indeed, his hesitation seemed reasonable: A volleyball team from my son’s high school spent most of their trip to China locked up in a Beijing hotel. And the Kawasaki delegation of Japanese scouts that part of our Boy Scout troop had been preparing to host for the better part of a year canceled their visit for fear of the porcine virus.
So I knew I was facing a turning point last night when I heard that Coach Bin had left for Shanghai, sticking me with a bunch of kids signed up for fencing lessons on Thursday night.
The news today confirmed my suspicions:
Sinovac Biotech Ltd. (AMEX:SVA) has developed a swine flu vaccine that is now safe. According to reports, it protects people after a single shot.
Inoculation has caused no severe adverse reactions in the 1,614 volunteers who received it, according to the company.
“The results are the first reported anywhere in the world on a vaccine to fight the new H1N1 strain that’s sparked the first influenza pandemic in 41 years,” said the company.
With U.S. vaccine manufacturers already behind schedule producing the amounts of vaccine ordered up by the U.S. government, that means Sinovac has the inside track on the world H1N1 vaccine market.
The stock rose over 10% today. Keep an eye on the stock… if U.S. manufacturers are not catching up, this one may be a medium-term winner.
*** Speaking of Chinese pharma stocks:
Last week, Laura Cadden closed out her refined refiner position of Sunoco, Inc. (NYSE:SAH) via stop loss at 20% gains. That was double-digit gainer #44 so far this year. (Which so far works out to about 5.5 gainers per month for HSC readers…)
But that’s really just for our official book-keeping. We know most of our HSC members are seasoned investors who may not need our constant hand-holding — but are looking to our team for investment ideas.
Which means that you can take profits on anything as your darn well please. Just like HSC member Sandra M., who wrote us this morning regarding one of the four “proxy stocks” we had recommended just a few weeks ago:
“Thanks for XYZ. I took my profit at 20% gain which paid my credit card bill this month. Thanks, Laura! Looking for a dip to get back in.”
That’s the spirit! Making money on HSC picks, even without us having to say a single word.
By the way, the -18% drop in the Shanghai market since August 4 has opened up some great buying opportunities for all four of our Chinese pharma stocks. I’m just saying… you might just want to re-read my initial report.
Next Article: TFN Reader Grapevine: Check out penny stocks lEnergtek Inc. (EGTK) and Sinobiopharma (SNBP)
Be the first to leave a reply.
Your comments are welcome
Follow TFN via RSS or Twitter |
 |
 |
 |
Advertisement
Latest Headlines
- The Big Picture for Sinobiopharma, Inc. (SNBP)
- Beazer Homes USA, Inc. (BZH) and Hovnanian Enterprises, Inc. (HOV) up despite horrid housing news
- The FDA catalyst: 2010 moves in MannKind (MNKD), Roche Holding (RHHBY), Acorda Therapeutics (ACOR) show it still works!
- Steepest drop since Feb. 2009: Here we go again!
- Is the silver run over? Coeur d’Alene Mines (CDE), Silver Wheaton (SLW), Alto Group (ALTO), Hecla Mining (HL), Endeavour Silver (EXK) close down